TAC4 (HK1), a potential drug target and biomarker for the treatment of hypertension

Target Name: TAC4

NCBI ID: G255061

TAC4

TAC4 (HK1), a potential drug target and biomarker for the treatment of hypertension

Abstract:

High blood pressure, or hypertension, is a major risk factor for cardiovascular disease and other chronic conditions. The finding an effective and safe drug target has always been a hot topic in the field of drug development. In recent years, scientists have discovered that TAC4 (HK1) may be a potential drug target. This article will introduce the basic information of TAC4 (HK1), its possible pharmacodynamic mechanism, and its advantages as a drug target.

1. Basic information of TAC4 (HK1)

TAC4 (HK1) is a protein that belongs to the transcription factor family and belongs to the H factor family. It plays an important regulatory role in chromatin structure and is mainly involved in gene expression and regulation. TAC4 (HK1) is expressed in a variety of tissues and organs, including heart, brain, liver, and kidney. In addition, TAC4 (HK1) is also expressed in vascular endothelial cells and may play a role in vascular endothelial growth and permeability.

2. Pharmacodynamic mechanism of TAC4 (HK1)

The pathophysiological mechanism of hypertension is very complex, including neuroendocrine, endocrine, immune and cytological aspects. The pharmacodynamic mechanism of TAC4 (HK1) mainly involves the following aspects:

1. Regulate blood vessel tone

One of the main pathophysiological mechanisms of hypertension is dysfunction of vascular endothelial cells, leading to increased vascular tone. TAC4 (HK1) can reduce the tone of vascular endothelial cells by regulating gene expression and cell signaling pathways, thereby reducing vascular tone and having a potential role in the treatment of hypertension.

2. Antioxidant effect

Oxidative stress is one of the important mechanisms causing cardiovascular disease in patients with hypertension. TAC4 (HK1) can inhibit oxidative stress by regulating the expression of antioxidant genes, thereby reducing blood pressure and having a potential role in the treatment of hypertension.

3. Participate in inflammatory response

Inflammatory response is one of the important mechanisms of cardiovascular disease in patients with hypertension. TAC4 (HK1) can inhibit the inflammatory response by regulating the expression of inflammatory factors, thereby lowering blood pressure and having a potential role in the treatment of hypertension.

4. Participate in cell proliferation and apoptosis

Vascular endothelial cells in patients with hypertension often exhibit abnormal proliferation and apoptosis, which is one of the main pathophysiological mechanisms of hypertension. TAC4 (HK1) can inhibit abnormal proliferation and apoptosis of vascular endothelial cells by regulating cell proliferation and apoptosis signaling pathways, thereby reducing blood pressure and having a potential role in the treatment of hypertension.

3. Advantages of TAC4 (HK1) as a drug target

As a potential drug target, TAC4 (HK1) has the following advantages:

1. High security

TAC4 (HK1) is a protein expressed in a variety of tissues and organs and is also expressed in vascular endothelial cells. Because TAC4 (HK1) is widely expressed, it is less likely to cause toxic side effects when used as a drug target.

2. Strong selectivity

TAC4 (HK1) is a selective protein that can selectively bind certain drug molecules, thereby improving the target effect of the drug. This makes TAC4 (HK1) a potential drug target.

3. High expression level

TAC4 (HK1) is expressed in a variety of tissues and organs, making it a potential drug target. In addition, the expression level of TAC4 (HK1) is also relatively stable, which provides stability for drug development.

4. Participate in various pathophysiological processes

TAC4 (HK1) is involved in a variety of pathophysiological processes, including regulating vascular tone, antioxidant effects, participating in inflammatory responses, and participating in cell proliferation and apoptosis. This makes TAC4 (HK1) a potential drug target.

4. Conclusion

TAC4 (HK1) is a potential drug target for the treatment of hypertension. By regulating vascular tone, antioxidant effects, participating in inflammatory responses, and participating in cell proliferation

Protein Name: Tachykinin Precursor 4

Functions: Tachykinins are active peptides which excite neurons, evoke behavioral responses, are potent vasodilators and secretagogues, and contract (directly or indirectly) many smooth muscles. Endokinin-A induces thermal hyperalgesia and pain-related behavior such as scratching following intrathecal administration in rats. These effects are suppressed by treatment with endokinin-C. Endokinin-A/B reduces arterial blood pressure and increases sperm motility

The "TAC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets